Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2026 ,inter alia, to consider and approve Financial Results as ....
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nath Bio-Genes has informed BSE and NSE that its Board of Directors will meet on Saturday, 31st January 2026 to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the quarter and nine months ended 31st December 2025. The intimation is filed under Regulation 29 and 33 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The company's trading window for insider trading has been closed from 31st December 2025 and will reopen on 03rd February 2026. No specific financial details or results have been disclosed in this filing.
This is a routine pre-results regulatory intimation with no direct impact on shareholders. Investors should watch for the actual Q3FY26 and 9MFY26 numbers and any management commentary when results are released after 31st January 2026.